RELA Drug Patent Profile
✉ Email this page to a colleague
When do Rela patents expire, and what generic alternatives are available?
Rela is a drug marketed by Schering and Smithkline Beecham and is included in two NDAs.
The generic ingredient in RELA is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rela
A generic version of RELA was approved as nabumetone by CHARTWELL RX on February 25th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RELA?
- What are the global sales for RELA?
- What is Average Wholesale Price for RELA?
Summary for RELA
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Patent Applications: | 3,876 |
| DailyMed Link: | RELA at DailyMed |
US Patents and Regulatory Information for RELA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | RELA | carisoprodol | TABLET;ORAL | 012155-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
